Advertisement

European Spine Journal

, Volume 28, Issue 6, pp 1468–1479 | Cite as

Clinical significance of traditional clinical parameters and inflammatory biomarkers for the prognosis of patients with spinal chondrosarcoma: a retrospective study of 150 patients in a single center

  • Kehan Xu
  • Bo Li
  • Quan Huang
  • Dongjie Jiang
  • Haitao Sun
  • Nanzhe Zhong
  • Wei WanEmail author
  • Haifeng WeiEmail author
  • Jianru XiaoEmail author
Original Article

Abstract

Background

To investigate the clinical significance of five inflammatory biomarkers and conventional clinical parameters in prognostic prediction of spinal chondrosarcoma.

Methods

Univariate and multivariate analyses were performed to investigate independent prognostic factors for recurrence and death of patients with spinal chondrosarcoma. Disease-free survival (DFS) and overall survival (OS) were estimated by Kaplan–Meier curve, and differences were analyzed by log-rank test. The optimal cutoff values for NLR, PLR, LMR, and CAR were determined by X-tile program.

Results

The optimal cutoff value for NLR, PLR, LMR, AGR, and CAR was 2.7, 200, 3.0, 1.5, and 0.2, respectively. Of the 150 patients included, recurrence was detected in 105 patients, and death occurred in 78 patients. Multivariate analysis indicated that Tomita I–III, total resection, and CAR < 0.2 were significantly associated with longer DFS. Meanwhile, preoperative Frankel score D–E, total resection, and CAR < 0.2 were favorable prognostic factors for OS. Subtype analysis showed that only total resection was an independent prognostic factor for DFS of recurrent spinal chondrosarcoma.

Conclusion

Total resection could significantly reduce the recurrence rate of spinal chondrosarcoma and improve OS of chondrosarcoma patients. Tomita classification I–III was a favorable factor for DFS, and preoperative Frankel score A–C was an adverse prognostic factor for OS. CAR was the most robust prognostic indicator with a discriminatory ability as compared with other inflammatory indicators.

Graphical abstract

These slides can be retrieved under Electronic Supplementary Material.

Keywords

Spinal chondrosarcoma Inflammatory biomarkers Disease-free survival Overall survival Prognosis 

Abbreviations

DFS

Disease-free survival

OS

Overall survival

NLR

Neutrophil-to-lymphocyte ratio

PLR

Platelet-to-lymphocyte ratio

LMR

Lymphocyte-to-monocyte ratio

AGR

Albumin/globulin ratio

CAR

C-reactive protein-to-albumin ratio

HR

Hazard ratio

CI

Confidence interval

Notes

Authors’ contributions

JX offered the research direction regarding the prognostic role of preoperative D-dimer and inflammatory biomarkers in spinal ESFTs. WF and WW designed the study and gave us several meaningful suggestions. JL, HS, and NZ reviewed and collected the medical records. QH and BL analyzed and interpreted the patient data. KX was a contributor in writing the manuscript. All authors read and approved the final manuscript.

Compliance with ethical standards

Conflict of interest

No conflict of interest exits in the submission of this manuscript, and manuscript is approved by all authors for publication. I would like to declare on behalf of my co-authors that the work described was original research that has not been published previously, and not under consideration for publication elsewhere, in whole or in part.

Ethical approval

All procedures involving human participants performed in studies were approved by Changzheng Hospital Ethics Committee, and informed consents were obtained from all patients or their legal guardians.

Consent for publication

Patients or their legal guardians know and approve the publication.

Supplementary material

586_2019_5993_MOESM1_ESM.pptx (27.5 mb)
Supplementary file1 (PPTX 28153 kb)

References

  1. 1.
    Riedel RF, Larrier N, Dodd L, Kirsch D, Martinez S, Brigman BE (2009) The clinical management of chondrosarcoma. Curr Treat Options Oncol 10:94–106CrossRefGoogle Scholar
  2. 2.
    Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH et al (2008) The clinical approach towards chondrosarcoma. Oncologist 13:320–329CrossRefGoogle Scholar
  3. 3.
    Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP (2009) Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am 91:1063–1072CrossRefGoogle Scholar
  4. 4.
    Strike SA, McCarthy EF (2011) Chondrosarcoma of the spine: a series of 16 cases and a review of the literature. Iowa Orthop J 31:154–159Google Scholar
  5. 5.
    Hogendoorn PC, Athanasou N, Bielack S, Bielack S, De Alava E, Dei Tos AP et al (2010) Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v204–v213CrossRefGoogle Scholar
  6. 6.
    Nota SP, Braun Y, Schwab JH, van Dijk CN, Bramer JA (2015) The identification of prognostic factors and survival statistics of conventional central chondrosarcoma. Sarcoma 2015:623746CrossRefGoogle Scholar
  7. 7.
    Xu J, Li D, Xie L, Tang S, Guo W (2015) Mesenchymal chondrosarcoma of bone and soft tissue: a systematic review of 107 patients in the past 20 years. PLoS ONE 10:e0122216CrossRefGoogle Scholar
  8. 8.
    Yin H, Zhou W, Meng J, Zhang D, Wu Z, Wang T (2015) Prognostic factors of patients with spinal chondrosarcoma: a retrospective analysis of 98 consecutive patients in a single center. Ann Surg Oncol 21:3572–3578CrossRefGoogle Scholar
  9. 9.
    Whelan J, Davis LE (2018) Osteosarcoma, chondrosarcoma, and chordoma. J Clin Oncol 36:188–193CrossRefGoogle Scholar
  10. 10.
    Tsukamoto S, Honoki K, Kido A, Fujii H, Enomoto Y, Ohbayashi C et al (2014) Chemotherapy improved prognosis of mesenchymal chondrosarcoma with rare metastasis to the pancreas. Case Rep Oncol Med 2014:249757Google Scholar
  11. 11.
    Vasudevan HN, Raleigh D, Johnson J, Garsa AA, Theodosopoulos PV, Aghi MK et al (2017) Management of chordoma and chondrosarcoma with fractionated stereotactic radiotherapy. Front Surg 4:35CrossRefGoogle Scholar
  12. 12.
    Strotman PK, Reif TJ, Kliethermes SA, Sandhu JK, Nystrom LM (2017) Dedifferentiated chondrosarcoma: a survival analysis of 159 cases from the SEER database (2001–2011). J Surg Oncol 116:252–257CrossRefGoogle Scholar
  13. 13.
    Arshi A, Sharim J, Park DY, Park HY, Bernthal NM, Yazdanshenas H et al (2017) Chondrosarcoma of the osseous spine: an analysis of epidemiology, patient outcomes, and prognostic factors using the SEER registry from 1973 to 2012. Spine (Phila Pa 1976) 42:644–652CrossRefGoogle Scholar
  14. 14.
    Li J, Li B, Zhou P, Wu Z, Yang X, Yang X et al (2017) Nomograms for prognostic factors of spinal giant cell tumor combining traditional clinical characteristics with inflammatory biomarkers after gross total resection. Oncotarget 8:86934–86946Google Scholar
  15. 15.
    Xu J, Shi KQ, Chen BC, Huang ZP, Lu FY, Zhou MT (2017) A nomogram based on preoperative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol 32:1394–1402CrossRefGoogle Scholar
  16. 16.
    Mantovani A, Allavena P, Sica A (2008) Cancer-related inflammation. Nature 454(436–444):2008Google Scholar
  17. 17.
    Diakos CI, Charles KA, McMillan DC (2014) Cancer-related inflammation and treatment effectiveness. Lancet Oncol 15:e493–e503CrossRefGoogle Scholar
  18. 18.
    Hirahara N, Matsubara T, Mizota Y, Ishibashi S, Tajima Y (2016) Prognostic value of preoperative inflammatory response biomarkers in patients with esophageal cancer who undergo a curative thoracoscopic esophagectomy. BMC Surg 16:66CrossRefGoogle Scholar
  19. 19.
    Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z et al (2013) Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol 31:1188–1195CrossRefGoogle Scholar
  20. 20.
    Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Shibuya N, Kubota K (2016) Clinical significance of the C-reactive protein to albumin ratio for survival after surgery for colorectal cancer. Ann Surg Oncol 23:900–907CrossRefGoogle Scholar
  21. 21.
    Frankel HL, Hancock DO, Hyslop G, Melzak J, Michaelis LS, Ungar GH (1967) The value of postural reduction in the initial management of closed injuries of the spine with paraplegia and tetraplegia I. Paraplegia. 7:179–192Google Scholar
  22. 22.
    Hobusch GM, Tiefenboeck TM, Patsch J, Krall C, Holzer G (2016) Do patients after chondrosarcoma treatment have age-appropriate bone mineral density in the long term? Clin Orthop Relat Res 474:1508–1515CrossRefGoogle Scholar
  23. 23.
    Zoccali C, Ferrraresi V, Rossi B, Covello R, Salducca N (2015) Intermediate grade vertebral osteosarcoma in a patient affected by a sacral chondrosarcoma and hereditary multiple exostosis. Minerva Med 106:115–117Google Scholar
  24. 24.
    Chen S, Wang Y, Su G, Chen B, Lin D (2016) Primary intraspinal dumbbell-shaped mesenchymal chondrosarcoma with massive calcifications: a case report and review of the literature. World J Surg Oncol 14:203CrossRefGoogle Scholar
  25. 25.
    Schoenfeld AJ, Hornicek FJ, Pedlow FX, Kobayashi W, Raskin KA, Springfield D et al (2012) Chondrosarcoma of the mobile spine: a review of 21 cases treated at a single center. Spine (Phila Pa 1976) 37:119–126CrossRefGoogle Scholar
  26. 26.
    Boriani S, De Iure F, Bandiera S, Campanacci L, Biagini R, Di Fiore M et al (2000) Chondrosarcoma of the mobile spine: report on 22 cases. Spine (Phila Pa 1976) 25:804–812CrossRefGoogle Scholar
  27. 27.
    Song K, Shi X, Wang H, Zou F, Lu F, Ma X et al (2018) Can a nomogram help to predict the overall and cancer-specific survival of patients with chondrosarcoma? Clin Orthop Relat Res 476:987–996CrossRefGoogle Scholar
  28. 28.
    Zhang S, Yang X, Wang L, Zhang C (2018) Interplay between inflammatory tumor microenvironment and cancer stem cells. Oncol Lett 16:679–686Google Scholar
  29. 29.
    Munn LL (2017) Cancer and inflammation. Wiley Interdiscip Rev Syst Biol Med.  https://doi.org/10.1002/wsbm.1370 Google Scholar
  30. 30.
    Li YJ, Yang X, Zhang WB, Yi C, Wang F, Li P (2017) Clinical implications of six inflammatory biomarkers as prognostic indicators in Ewing sarcoma. Cancer Manag Res 9:443–451CrossRefGoogle Scholar
  31. 31.
    Ehrenstein V, Andersen SL, Qazi I, Sankar N, Pedersen AB, Sikorski R et al (2017) Tenosynovial giant cell tumor: incidence, prevalence, patient characteristics, and recurrence. A registry-based cohort study in Denmark. J Rheumatol 44:1476–1483CrossRefGoogle Scholar
  32. 32.
    Li YJ, Yao K, Lu MX, Zhang WB, Xiao C, Tu CQ (2017) Prognostic value of the C-reactive protein to albumin ratio: a novel inflammation-based prognostic indicator in osteosarcoma. Onco Targets Ther 10:5255–5261CrossRefGoogle Scholar
  33. 33.
    Roxburgh CS, McMillan DC (2014) Cancer and systemic inflammation: treat the tumor and treat the host. Br J Cancer 110:1409–1412CrossRefGoogle Scholar
  34. 34.
    Ji H, Houghton AM, Mariani TJ, Perera S, Kim CB, Padera R et al (2006) K-ras activation generates an inflammatory response in lung tumors. Oncogene 25:2105–2112CrossRefGoogle Scholar
  35. 35.
    Lissoni P, Brivio F, Fumagalli L, Messina G, Ghezzi V, Frontini L et al (2004) Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers 19:135–140CrossRefGoogle Scholar
  36. 36.
    Ishikawa S, Miyashita T, Inokuchi M, Hayashi H, Oyama K, Tajima H et al (2016) Platelets surrounding primary tumor cells are related to chemoresistance. Oncol Rep 36:87–794Google Scholar
  37. 37.
    Xu K, Lou Y, Sun R, Liu Y, Li B, Li J et al (2019) Establishment of a nomogram-based model for predicting the prognostic value of inflammatory biomarkers and preoperative D-dimer level in spinal Ewing’s sarcoma family tumors: a retrospective study of 83 patients. World Neurosurg 121:e104–e112CrossRefGoogle Scholar
  38. 38.
    Tsavaris O, Economopoulou P, Kotsantis I, Reppas L, Avgerinou C, Spathas N et al (2018) Clinical benefit of pazopanib in a patient with metastatic chondrosarcoma: a case report and review of the literature. Front Oncol 8:45CrossRefGoogle Scholar
  39. 39.
    Chen D, Chen CH, Zhang LL, Lin ZK, Zheng JW, Phan K et al (2018) Chondrosarcoma of the osseous spine treated by surgery with or without radiotherapy: a propensity score matched and grade/stage-stratified study. Clin Spine Surg 31:E310–E316CrossRefGoogle Scholar
  40. 40.
    Tomita K, Kawahara N, Kobayashi T et al (2001) Surgical strategy for spinal metastases. Spine 26:298–306CrossRefGoogle Scholar
  41. 41.
    Ju DG, Zadnik PL, Groves ML, Hwang L, Kaloostian PE, Wolinksy JP et al (2013) Factors associated with improved outcomes following decompressive surgery for prostate cancer metastatic to the spine. Neurosurgery 73:657–666CrossRefGoogle Scholar
  42. 42.
    Crnalic S, Hildingsson C, Wikstrom P, Bergh A, Löfvenberg R, Widmark A et al (2012) Outcome after surgery for metastatic spinal cord compression in 54 patients with prostate cancer. Acta Orthop 83:80–86CrossRefGoogle Scholar
  43. 43.
    Kurdi M, McGregor S, Hammond R, Bergh A, Löfvenberg R, Widmark A et al (2010) Primary clear cell chondrosarcoma of thoracic spine. Int J Surg Pathol 25:181–184CrossRefGoogle Scholar
  44. 44.
    Bindiganavile S, Han I, Yun JY, Kim HS (2015) Long-term outcome of chondrosarcoma: a single institutional experience. Cancer Res Treat 47:897–903CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Orthopedic Oncology, Changzheng HospitalSecond Military Medical UniversityShanghaiPeople’s Republic of China

Personalised recommendations